ascopubs.org

Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan

The combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data ...
Nature

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal proliferation and differentiation blockade of myeloid precursors in the bone marrow [1,2,3]. Despite ...
Healio

VIDEO: Weaving older, newer agents into clinical practice for AML

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I used most of these agents in practice in ...
Nature

Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia

Immunotherapeutic approaches have become increasingly important in cancer therapy, including for patients with acute myeloid leukemia (AML). Despite being shown to be effective in the context of stem ...
Taiwan News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed AML ...